ABSTRACT Introduction Interleukin-6 receptor (IL-6R) blockade improves the signs and symptoms of rheumatoid arthritis (RA) and retards bone damage. Whether IL-6R blockade allows repair of existing bone erosions is so far unclear. Methods This study examined bone erosions in the metacarpophalangeal joints of 20 patients receiving treatment with the IL-6R blocker tocilizumab using micro CT (μCT). The maximal width and depth of individual bone erosions was measured at baseline and after 1 year of treatment.
Bone erosion is a hallmark of rheumatoid arthritis (RA) refl ecting the tight interaction between infl ammation, structural damage and functional disability. [1] [2] [3] Bone erosion results from a chronic infl ammatory process in the synovial membrane and adjacent bone marrow, which triggers skeletal damage particularly at the 'bare areas' of the joint, where bone is not covered by cartilage. Pathogenesis of bone erosion is based on local expression of infl ammatory cytokines, such as the receptor activator of nuclear factor kappa B ligand (RANKL) and tumour necrosis factor (TNF) alpha, which stimulate the differentiation of synovial monocytes/macrophages into osteoclasts and triggers the resorption of cortical bone. 4 Destruction of bone and the covering cartilage has been shown to be closely related to functional decline in RA patients, 2 3 and antirheumatic therapies attempt to EXTENDED REPORT Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study Stephanie Finzel, 1 Juergen Rech, 1 Sarah Schmidt, 1 Klaus Engelke, 2 Matthias Englbrecht, 1 Georg Schett 1 retard, stop or even reverse structural bone damage in arthritis to maintain or even improve the patients' disease state. 5 Antirheumatic drugs show specifi c effects on the periarticular bone, which are related to the magnitude and the quality of their bone-protective action. 5 Bone-protective effects of antirheumatic drugs are usually based on their anti-infl ammatory properties, which allow control of synovitis, and their direct effects on the bone-resorptive process by affecting osteoclast differentiation. Retardation and even arrest of progression of bone erosion is a well-known effect of antirheumatic drugs, which appears to be particularly strong with TNF blocking agents. Much less, however, is known about the possibility of repair of existing bone erosions and whether and how cytokine blockade infl uences this process.
The principal possibility of repair of existing bone erosions has been obtained from radiographic studies, [6] [7] [8] [9] which have been later supported by MRI, CT and ultrasound. 10 11 We have recently developed a high-resolution imaging technique to measure the dimensions of single bone erosions exactly. 12 Its high resolution combined with direct visualisation of bone allows micro CT (μCT) to detect even tiny changes in the dimensions of single bone erosions and thereby allows the assessment of repair. By using μCT, it has been shown that repair is associated with the apposition of bone at the bottom of the lesions resulting in partial refi lling of the lesions. 13 It is unknown whether other cytokine-blocking strategies also allow repair of existing bone erosions. We therefore decided to search for evidence of repair in RA patients treated with the neutralising interleukin-6 receptor (IL-6R) antibody tocilizumab, because interleukin 6 (IL-6) has been shown to regulate bone homeostasis by affecting osteoblast and osteoclast function. 14 To accomplish this goal, we performed a sequential μCT analysis of bone erosions in RA patients treated with tocilizumab over 1 year to determine exactly the occurrence of repair.
METHODS Patients
Twenty RA patients were included in this study. All patients fulfi lled the 1987 American Rheumatism Association revised criteria for the classifi cation of RA, 15 as well as the new 2010 American College of Rheumatology/ European League Against Rheumatism classifi cation criteria for RA, 16 and were recruited at the rheumatology outpatient clinic of the University Clinic of Erlangen. All patients received treatment with the neutralising antibody against IL-6R tocilizumab at a dose of 8 mg/kg body weight in combination with methotrexate (mean dose of methotrexate 12.88 mg/week). Treatment of tocilizumab as well as methotrexate was stable for at least 3 months before the baseline μCT examination. The study was performed in accordance with the Declaration of Helsinki. Approval from the local ethics committee and national radiation safety agency (Bundesamt für Strahlenschutz) as well as written informed consent was obtained for the study.
Imaging procedures
All patients received a μCT scan of the second to fourth metacarpophalangeal joints of the right hand at baseline (start of tocilizumab treatment) and at follow-up after 1 year. The μCT scans were performed with an XtremeCT scanner (SCANCO Medical AG, Brüttisellen, Switzerland) at a resolution of 82×82×82 μm voxel size. The scan region was 80 slices distal and 242 slices proximal of the upper margin of the third metacarpal head. Scan time was 8 min per patient and scan. For exact positioning the hand was positioned in a neutral posture and was padded. 10 A single investigator (SF) trained in the technique performed all scans.
Evaluation of images
The width and depth of bone erosions in the metacarpophalangeal joint of the second, third and fourth fi ngers were assessed. Erosions were defi ned as a break of the juxta-articular cortical bone. All erosions were documented both at baseline and after 1 year (follow-up). Evaluation of overall 322 two-dimensional μCT slices in the axial, sagittal and coronal plane was performed using the open source DICOM viewer (Rosslyn, VA, USA) Osirix V3.2. Assessment included the palmar, ulnar, dorsal as well as the radial quadrants of the metacarpal heads and the phalangeal bases. 12 Individual bone erosions were both characterised by metrical assessment of the maximal width and depth of the cortical breaks. 12 In addition, any signs of bone apposition at the base of the erosion were documented. Evaluation of the maximal width of erosion, maximal depth of erosion and the presence/absence of sclerosis was performed by two readers (KE and SS), blinded to the sequence of scans as well as the patient's identity. Based on the presence or absence of sclerosis at baseline or follow-up, respectively, erosions were classifi ed as 'non-sclerosing', in which all erosions showed no bone apposition either at baseline or at follow-up; 'sclerosing' erosions were defi ned as bone apposition absent at baseline but present at follow-up; 'sclerosed' were all erosions with bone apposition both at baseline and follow-up, as described previously. 13 Intraobserver reproducibility both for erosion width and depth (SS) was very high (intraclass correlation 0.99) and also interobserver reproducibility (KE and SS) was high (intraclass correlations: erosion width 0.93, erosion depth 0.94). The smallest detectable change of erosion depth and erosion width was calculated on the basis of 25 individual erosions, as suggested by Bruynesteyn et al 17 and was extremely low (0.008 mm both for erosion width and depth). Readings performed by SS were used for further comparisons.
Statistics
The width and depth of cortical breaks were Gaussian distributed at baseline and at follow-up. Paired student's t test was used for comparison of groups. Calculations were performed with SPSS program version 17.0. A p value of less than 0.05 was considered statistically signifi cant.
RESULTS

Baseline characteristics of patients and bone erosions
Twenty patients receiving tocilizumab therapy were included in this study: all of them were followed over 1 year and received μCT-based assessment of the second, third and fourth metacarpophalangeal joints to measure exactly all bone erosions at baseline after 1 year for reassessment. Seventeen patients were women and three were men, with a mean±SD age of 50.7±13.5 years and a mean±SD disease duration of 11.1±8.8 years. Mean disease activity at baseline according to the disease activity score using 28 joint counts (DAS28) was 5.48±2.38, at baseline showing active disease with signifi cant improvement in the signs and symptoms of RA after 1 year (mean±SD DAS28 3.25±1.13).
We found at total number of 133 bone erosions at baseline. All these 133 lesions could be visualised again at follow-up examination. In addition, nine new erosions were detected at followup. The mean (±SD) width of bone erosions was 2.23±1.26 mm, mean (±SD) depth was 2.16±1.50 mm. Erosions showed a standard distribution pattern, as reported previously, 12 with preferential involvement of the second (49%) compared with the third (29%) and fourth (22%) metacarpophalangeal joints, the metacarpal heads (62%) compared with the phalangeal bases (38%) and the radial joint compartment (37%) compared with the ulnar (26%), dorsal (19%) and palmar (18%) joint compartments (fi gure 1).
Effects of tocilizumab therapy on the size of individual bone erosions
We next compared the changes in maximal width and depth of the 133 bone erosions found at baseline and follow-up examination. The width of bone erosions signifi cantly (p=0.014) We have previously shown that sclerosis in individual bone erosions is associated with a reduction in the size of lesions in patients treated with TNF blocking agents. 13 Indeed, the association between sclerosis and repair was also seen in patients receiving tocilizumab. Erosions with no evidence of sclerosis at baseline and follow-up ('non-sclerosing') did not show evidence of repair (mean±SEM change in width 0.02±0.15 mm, mean±SEM change in depth 0.09±0.14 mm). However, the absolute number of non-sclerosing lesions was rather low (N=24). In contrast, erosions showing sclerosis at baseline ('sclerosed') were most abundant (N=78) and showed clear evidence of repair (mean±SEM change in width −0.14±0.05 mm, p=0.0086; mean±SEM change in depth −0.20±0.09 mm, p=0.038). Also, lesions with no sclerosis at baseline but sclerosis at follow-up ('sclerosing', N=31) showed evidence of repair, particularly in the reduction in the width of lesions (mean±SEM change in width −0.20±0.08 mm, p=0.019; mean±SEM change in depth 0.05±0.09 mm, not signifi cant) (fi gure 2A,B). Representative examples of bone erosion showing evidence of repair are shown in fi gure 2C.
Anatomical distribution of erosion repair in RA patients treated with tocilizumab
We were next interested in whether repair preferentially occurs at certain anatomical areas. We therefore analysed the mean changes of erosion width and depth at 24 different joint regions (fi gure 3). The analysis of erosion width showed that those joint compartments most affected by bone erosions such as the second metacarpophalangeal joint reveal the most consistent evidence of repair. When analysing the anatomical predilection sites for the reduction in erosion depth the radial compartments of the second and third metacarpal heads showed most evidence of repair.
Erosion size and repair in RA patients treated with tocilizumab
We next analysed whether the size of erosions predicts repair. We therefore created quartiles according to the width and depth of bone erosions (fi gure 4A,B). We performed this analysis for both sclerosed and sclerosing bone erosions, as evidence of repair was confi ned to these two categories of erosions. Analysis of different quartiles for erosion width showed that repair was confi ned to larger lesions of more than 1.76 mm (quartiles 3 and 4; both p<0.05) for sclerosed lesions and 2.55 mm (quartiles 3 and 4; both p<0.05) for sclerosing lesions. Similar results were obtained when analysing the different quartiles of erosion depth. Sclerosed lesions with a depth of more than 1.60 mm (quartiles 3 and 4, both p<0.05) but not the smaller ones (quartiles 1 and 2) showed evidence of repair. With sclerosing lesions those over 3.31 mm in depth (quartile 4) showed a strong trend towards repair, although results did not reach statistical signifi cance.
The preponderance of repair in larger bone erosions also became evident from the analysis of probability plots for changes in erosion width and depth. When plotting changes in erosion width and depth in patients treated with tocilizumab, lesions with repair, arrest and progression can be identifi ed (fi gure 4C). Larger lesions (quartiles 3 and 4) accumulated in the left negative part of the probability plot indicating a higher prevalence of repair (fi gure 4D). For instance 71.4% of the lesions with evidence of substantial repair (>0.5 mm decrease in width) were larger lesions, whereas only 6.7% of lesions with substantial progression (>0.5 mm increase in width) were larger erosions.
DISCUSSION
By using μCT, a high-resolution imaging technique designed for the quantitative analysis of bone, we show that therapy with the IL-6R blocker tocilizumab allows limited repair of bone erosions. Although repair was incomplete and all of the 133 bone erosions detected at baseline could be revisited at follow-up, treatment with tocilizumab was associated with an improvement in the width of cortical breaks as well as their depth. Repair was closely linked to evidence of sclerosis, which probably refl ects new bone formation as well as the baseline size of erosions, with larger lesions showing a higher likelihood of repair. Importantly, the readers of the images were unaware of the changes in erosion width, erosion depth and sclerosis between baseline and follow-up, thus ruling out that judgement on the presence or absence of sclerosis infl uenced data on the changes in erosion width and depth.
Several previous studies have reported that repair of bone erosions can occur in RA patients. 6-11 13 These studies, however, have also suggested that repair is limited and confi ned to a subset of lesions. 10 11 13 RA patients treated with TNF inhibitors appear preferentially to show evidence of repair. 9-11 13 We recently confi rmed this notion by a μCT study, which showed clear evidence for the limited repair of bone erosions in patients treated with TNF inhibitors compared with patients treated with methotrexate. 13 Interestingly, erosion repair on treatment with TNF inhibitors is also almost exclusively confi ned to larger lesions with evidence of sclerosis, which is in high accordance with our new data obtained in RA patients treated with tocilizumab. Why larger erosions show a higher likelihood of repair than smaller lesions is not fully understood, but may involve contact with the bone marrow space required to induce the skeletal repair process and time factors, as osteoblastic responses require time to allow suffi cient cell differentiation, deposition of matrix and mineralisation and larger lesions may be older.
Whether there is evidence of erosion repair in tocilizumabtreated RA patients, as previously reported in TNF inhibitor-treated patients, remains speculative. Despite similar baseline erosion size and a very similar mean change in the size of bone erosions after 1 year among the previously analysed TNF inhibitor-treated RA patient cohort and this cohort of tocilizumab-treated RA patients, their baseline erosion count was substantially different, with signifi cantly more baseline bone erosions in the tocilizumab cohort. Therefore, we could not perform a direct comparison of the two patient groups as the likelihood of repair may depend on the baseline erosion count. It can be speculated, however, that the degree of erosion repair is comparable in tocilizumab and TNF inhibitor-treated RA patients as the higher baseline erosion count in the tocilizumab cohort is a negative selection bias and may underestimate the potential of tocilizumab to induce repair of existing bone lesions. Qualitative differences, however, may exist in the repair of erosions between IL-6 and TNF blockade. IL-6 blockade thus also affects the size of the cortical break (erosion width), whereas erosion repair during TNF blockade is exclusively based on the reduction of erosion depth, 13 which may indicate the preferential use of either periosteal and endosteal repair processes among these two cytokine-blocking modalities.
The pathophysiological background of the limited repair of bone erosions in RA patients treated with tocilizumab is probably based on the effects of IL-6 on bone remodelling. IL-6 is a strong inducer of osteoclast differentiation by at least two different pathways. It can directly stimulate differentiation of mononuclear cells to osteoclasts by forming complexes with the soluble IL-6R followed by stimulation of osteoclasts lineage cells through the membrane-bound glycoprotein 130. [18] [19] [20] [21] Blockade of the IL-6R by neutralising antibodies has recently been shown to abrogate this direct osteoclastogenic effect of IL-6. 22 In addition, IL-6 also acts on osteoblast lineage cells, where it induces RANKL and indirectly stimulates osteoclastogenesis. [23] [24] [25] [26] [27] Both the direct and indirect inhibition of osteoclast differentiation explains the strong structure-sparing effects of tocilizumab and also represents a prerequisite for allowing the repair of erosions. Repair of erosions requires the attraction and differentiation of osteoblast precursors to the sites of bone erosion. This process can only occur when osteoclast-mediated bone resorption is turned off, allowing the accessibility of eroded bone surface to osteoblasts. Inhibition of osteoclast-mediated bone resorption by tocilizumab can thus be seen as an important step towards bone repair.
However, whether toclizumab fosters new bone formation, which is compromised in bone erosions of patients with RA 27 by, for instance, affecting osteoblast recruitment and differentiation is not fully clear. Strong evidence for a shift towards increased bone formation, however, comes from the sequential analysis of bone biomarkers in the randomised controlled OPTION trial. 28 In that study, biomarkers of bone formation such as osteoclacin and N-terminal propeptide of type I collagen showed a signifi cant increase from baseline in response to tocilizumab. Preliminary data from the effects of tocilizumab in juvenile idiopathic arthritis, in which bone formation is blunted by infl ammation and leads to growth retardation of the affected child, suggests that the blockade of IL-6R restores normal bone formation facilitating normal skeletal development and repair. 29 30 These favourable effects of IL-6R blockade on bone formation may be primarily based on the effective blockade of infl ammation as the role of IL-6 on osteoblast lineage cells is not necessarily detrimental. Although data have suggested that IL-6 may block osteoblast function, 31 and mice transgenic for IL-6 show low bone formation, 32 other data revealed that IL-6 is important for osteoblast recruitment and may even foster osteoblast differentiation by the induction of insulin-like growth factor 1. [33] [34] [35] In summary, these data show that Il-6R blockade is associated with repair of bone erosions in patients with RA. Repair is based on reduction in the width and depth of the erosion, which is somewhat different from the effect of TNF inhibitors, in which repair is based on lowering erosion depth but not width. Repair with tocilizumab is, however, limited, as observed with TNF inhibitors, and does not lead to complete healing of erosions, which suggests that current antirheumatic therapies have a rather limited potential to induce the repair of bone lesions.
